Valery J. Kogler

Valery J. Kogler

Auto-generated profile, based on publicly available information

Valery J. Kogler

Department of Pathology and Laboratory Medicine, University of Virginia, Charlottesville, Virginia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Blood
Verified
Journal Article
Open access
PDF file
VKValery J. Kogler
Valery J. Kogler
MSMoritz Stolla
Moritz Stolla
More than 100 years ago, Duke transfused whole blood to a patient with thrombocytopenia to raise the platelet count and prevent bleeding. Since then, platelet transfusions have undergone numerous modifications from whole blood–derived platelet-rich plasma to apheresis-derived platelet concentrates. The storage time and temperature have also changed. The mandate to store platelets for a maximum of 5 to 7 days at room temperature has been challenged by recent clinical trial data, ongoing difficulties with transfusion-transmitted infections, and recurring periods of shortages that were further exacerbated by the COVID-19 pandemic. Alternative platelet storage approaches are as old as the first platelet transfusions. Cold-stored platelets may offer increased storage times (days) and improved hemostatic potential at the expense of reduced circulation time. Frozen (cryopreserved) platelets extend the storage time to years but require storage at −80°C and thawing before transfusion. Lyophilized platelets can be powder-stored for years at room temperature and reconstituted within minutes in sterile water but are probably the least explored alternative platelet product to date. Finally, whole blood offers the hemostatic spectrum of all blood components but has challenges such as ABO incompatibility. We know more than ever before about the in vitro properties of these products, and clinical trial data are accumulating. The purpose of this review is to summarize the findings of recent preclinical and clinical studies on alternative, donor-derived platelet products.

16 May 2024 in Blood
Verified
Journal Article
Open access
PDF file
VKValery J Kogler
Valery J Kogler
JMJeffrey Miles
Jeffrey Miles
TOTahsin Ozpolat
Tahsin Ozpolat
SBS Lawrence Bailey
S Lawrence Bailey
DBDaire Ann Byrne
Daire Ann Byrne
MSMoritz Stolla
Moritz Stolla
Platelets are stored at room temperature for 5 to 7 days (room temperature–stored platelets [RSPs]). Because of frequent and severe shortages, the US Food and Drug Administration recently approved up to 14-day cold-stored platelets (CSPs) in plasma. However, the posttransfusion function of CSPs is unknown and it is unclear which donors are best suited to provide either RSPs or CSPs. In this study, we sought to evaluate the posttransfusion platelet function and its predictors for platelets stored for the maximum approved storage times (7-day RSPs and 14-day CSPs) in healthy volunteers on acetylsalicylic acid (ASA). We conducted a randomized crossover study in 10 healthy humans. Individuals donated 1 platelet unit, stored at either 22°C or 4°C based on randomization. Before transfusion, participants ingested ASA to inhibit endogenous platelets. Transfusion recipients were tested for platelet function and lipid mediators. Platelet units were tested for lipid mediators only. A second round of transfusion with the alternative product was followed by an identical testing sequence. RSPs reversed platelet inhibition significantly better in αIIbβ3 integrin activation–dependent assays. In contrast, CSPs in recipients led to significantly more thrombin generation, which was independent of platelet microparticles. Lysophosphatidylcholine-O species levels predicted the procoagulant capacity of CSPs. In contrast, polyunsaturated fatty acid concentrations predicted the aggregation response of RSPs. In summary, we provide, to our knowledge, the first efficacy data of extended-stored CSPs in plasma. Our results suggest that identifying ideal RSP and CSP donors is possible, and pave the way for larger studies in the future. This trial is registered at www.ClinicalTrials.gov as #NCT0511102.

24 September 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
VKValery Kogler
Valery Kogler
MPMonica B. Pagano
Monica B. Pagano
MFMagali J. Fontaine
Magali J. Fontaine
VAVahid Azimi
Vahid Azimi
RBRachel Brancamp
Rachel Brancamp
AZAlyssa Ziman
Alyssa Ziman

30 June 2025 in Transfusion
Verified
Journal Article
Closed access
RGRaeshun Glover
Raeshun Glover
BYBettie Yeboah
Bettie Yeboah
RVRalph R. Vassallo
Ralph R. Vassallo
MSMoritz Stolla
Moritz Stolla
SPSandhya R. Panch
Sandhya R. Panch
JGJames D. Gorham
James D. Gorham